Forbes Feb. 23, 2022

Moderna Stock Crash Worsens Even After Morgan Stanley Says Flu Vaccine Results Could Boost Shares

Topline

In a glimmer of hope for one of this year’s worst-performing stocks, Morgan Stanley analyst Matthew Harrison projected incoming results for one of Moderna’s flu vaccine candidates would likely be a promising development for the firm’s struggling stock, joining a growing crop of experts looking to Moderna’s potential suite of offerings—and not necessarily its Covid-19 vaccine—as a catalyst for growth, even as shares continue to plummet.

Read more ....